Drug Profile
Research programme: stem cell modulators - Precigen Inc/Superview Biotechnology
Latest Information Update: 11 Feb 2020
Price :
$50
*
At a glance
- Originator MediStem Laboratories; Superview Biotechnology
- Developer Medistem; Superview Biotechnology
- Class Monoclonal antibodies
- Mechanism of Action Stem cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 12 Mar 2014 No development reported for Undefined indication (unspecified route)
- 07 Mar 2014 Medistem has been acquired by Intrexon Corporation